

Original Article

Mechanism underlying synergic activation of Tyrosinase promoter by MITF and IRF4

Jian Song^{1,2*}, Xueming Liu^{3*}, Jiada Li⁴, Huadie Liu⁴, Zhen Peng⁴, Yalan Liu^{1,2}, Lingyun Mei^{1,2}, Chufeng He^{1,2}, Xinzhang Cai^{1,2}, Hongsheng Chen^{1,2}, Kris Vleminckx^{5,6}, Yong Feng^{1,2,4*}

¹Department of Otolaryngology, Xiangya Hospital, Central South University, Changsha, People's Republic of China; ²Province Key Laboratory of Otolaryngology Critical Diseases, Changsha, People's Republic of China; ³Eye & Ear Infirmary Shandong Provincial Hospital Group, Shandong, People's Republic of China; ⁴State Key Laboratory of Medical Genetics, Central South University, Changsha, People's Republic of China; ⁵Department of Medical Genetics, Ghent University/Ghent University Hospital, De Pintelaan, Ghent, Belgium; ⁶Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium. *Co-first authors.

Received February 16, 2017; Accepted March 17, 2017; Epub April 15, 2017; Published April 30, 2017

Abstract: Background: The transcription factor interferon regulatory factor 4 (IRF4) was identified to be involved in human pigmentation by genome-wide association studies (GWASs). The rs12203592-[T/C], which is located in intron 4 of IRF4, shows the strongest link to these pigmentation phenotypes including freckling, sun sensitivity, eye and hair color. Previous studies indicated a functional cooperation of IRF4 with Microphthalmia-associated transcription factor (MITF), a causing gene of Waardenburg syndrome (WS), to synergistically trans-activate Tyrosinase (TYR). However, the underlying mechanism is still unknown. Methods: To investigate the importance of DNA binding in the synergic effect of IRF4. Reporter plasmids with mutant TYR promoters was generated to locate the IRF4 DNA binding sites in the Tyrosinase minimal promoter. By building MITF and IRF4 truncated mutations plasmids, the necessary regions of the synergy functions of these two proteins were also located. Results: The cooperative effect between MITF and IRF4 was specific for TYR promoter. The DNA-binding of IRF4 was critical for the synergic function. IRF4 DNA binding sites in TYR promoter were identified. The Trans-activation domains in IRF4 (aa134-207, aa300-420) were both important for the synergic function, whereas the auto-mask domain (aa207-300) appeared to mask the synergic effect. Mutational analysis in MITF indicated that both DNA-binding and transcriptional activation domains were both required for this synergic effect. Conclusions: Here we showed that IRF4 potently synergized with MITF to activate the TYR promoter, which was dependent on DNA binding of IRF4. The synergic domains in both IRF4 and MITF were identified by mutational analysis. This identification of IRF4 as a partner for MITF in regulation of TYR may provide an important molecular function for IRF4 in the genesis of melanocytes and the pathogenic mechanism in WS.

Keywords: MITF, IRF4, TYR, synergy effects, transcriptional activation

Introduction

Pigmentation is the most visible trait in humans. Nearly 200 genes have been identified in mice that play a role in pigment system affecting various steps in the development of melanocytes, a cell population derived from the neural crest. Several common variations associated with abnormal pigmentation have been identified from these genes. In a recent genome-wide association study (GWAS), several sequence variants on interferon regulatory factor 4 (IRF4) were linked to human pigmentation [1-3].

Variants in the IRF4 have been suggested to be associated with specific pigmentation phenotypes. The rs12203592 located in intron 4 of IRF4 show the strongest link to these pigmentation phenotypes [2-5]. IRF4 belongs to the Interferon Regulatory Factors (IRFs), a family of wing-helix-turn-helix structure forms of transcription factors initially identified as downstream regulators of interferon signaling. As previously described, it is mainly expressed in cells of the immune system where it transduces signals from various receptors to activate or repress expression of key regulators of lym-

Synergic activation of TYR promoter by MITF and IRF4




Figure 1. The effect of MITF and IRF4 on the TYR, DCT and 4M-box promoters in HEK293 cells (A) and UACC903 melanoma cells (B). HEK293T cells and UACC903 melanoma cells were transfected with MITF, IRF4 or MITF+IRF4 expression plasmids together with different report plasmids. The red bars (Control) indicate co-transfection with the empty vector as a negative control. Each value represents the mean \pm SD of three replicates from a single assay. The results shown were representative of at least three independent experiments (***) $P < 0.001$ compare to the value from the MITF and MITF+IRF4, unpaired Student's t-test).

phoid, myeloid, and dendritic cell development. A few studies have mentioned the association of IRF4 with pigmentation. The expression of IRF4 was found and identified in the skin and the G361 melanoma cell lines and correlated with MITF expression in melanoma cells [6-8].

Waardenburg syndrome is a clinically rare genetic disorder, characterized by pigmentation-related syndromic deafness. Its main clinical phenotypes are deafness and pigmentation anomalies, the latter of which are majorly manifested as heterochromia iridium, white forelock, premature graying of the hair, skin hypopigmentation or hyperpigmentation [9-11]. As one of the important causing genes of WS, The transcription factor *MITF* plays an critical role in the induction of melanocytes and is also necessary for their survival and/or differentiation. MITF was shown to regulate several genes involved in pigmentation, including the tyrosinase and tyrosine-related genes, *TYRP1* and *DCT*, by binding to their promoters through an E box motif (CANNTG).

Functional analysis indicates that IRF4 and MITF cooperate to activate transcription of TYR [4], but the mechanism of this synergy still remains unclear. To date, due to the high genetic heterogeneity in WS, there are still a signifi-

cant number of patients with an unidentified disease-causing gene.

Methods and materials

Plasmids constructions

MITF expression plasmid (pCMV-Flag-MITF) and TYR promoter reporter plasmid (pGL3-Tyr-Luc) were described previously [12, 13]. DCT (Another enzyme important during eumelanogenesis) and 4M-box promoter (a synthetic construct with 4 M-boxes in a row) reporter plasmid were kindly provided by Prof Hideki Murakami. The wild-type human IRF4 cDNA (NM_002460.3) was cloned into the pcDNA3.0-HA. To map the IRF4 DNA binding site in TYR promoter, a series of mutant TYR-luc constructs were synthesized by the Sangon Biotech (Shanghai) company and verified by sequencing (**Figure 2B**). To map the synergic domain of IRF4 and MITF, several mutant constructs were generated by PCR and cloned into pcDNA3 and pCMV separately. All constructs were verified by sequencing.

Transfection and luciferase assay

HEK293T (human embryonic kidney) and melanoma UACC903 cells were maintained in Dulbecco's modified Eagle medium (DMEM)

Synergic activation of TYR promoter by MITF and IRF4




Figure 2. A. The human TYR promoter (-300 to 80) shows the sequence of the MITF binding sites (E-box and M-box) and potential IRF4-binding sites (BS1-BS4). B. Schematic view of mutant TYR promoters (TYR1-TYR8). C. Effect of MITF, IRF4 on mutant TYR promoters (TYR1-TYR8) determined by luciferase activity assays in HEK293 cells. The red bars (Control) indicate co-transfection with the empty vector as a negative control. The WT and 8 mutant luciferase reporter plasmids were respectively transfected into 293T cells in combination with MITF, IRF4 and MITF+IRF4 expression plasmids. Each value represents the mean \pm SD of three replicates from a single assay. The results shown were representative of at least three independent experiments (** $P < 0.01$, *** $P < 0.001$ compare to the value from the MITF and MITF+IRF4, unpaired Student's t-test).

supplemented with 10% fetal bovine serum (FBS), 100 U/ml of Penicillin/Kanamycin, NEAA, Fungzone and cultured in an incubator at 37°C with 5% CO₂. HEK293T and UACC903 cells

were seeded in 24-well plates and transfected with expression and report plasmids using Fugene transfection reagent (Promega) according to the manufacturer's protocol. For measur-

Synergic activation of TYR promoter by MITF and IRF4




Figure 3. Identification of IRF4 sequences involved in synergic transactivation with MITF. A. A schematic representation of the full length IRF4 and various truncated IRF4 proteins. DBD, DNA binding domain. AMD, automatic mask domain. TAD, Trans-activation domain. B. HEK293T cells were transiently transfected with the TYR luciferase reporter and full length or truncated IRF4 expression plasmids including with MITF. Luciferase activity is reported as a fold increase relative to reporter alone. Each value represents the mean \pm SD of three replicates from a single assay. The results shown were representative of at least three independent experiments (***) $P < 0.001$ compare to the value from the wt IRF4 and different IRF4 mutants, unpaired Student's t-test).

ing MITF and IRF4 synergy effect on different promoter study, the IRF4-DNA binding site searching study and the IRF4 and MITF synergy domain identification study, each well contains 250 ng expression plasmids with 166 ng of the reporter plasmids.

Additionally, transfection of 66 ng of pGL3 control vector (Cat.# E1741) served as a transfection control and was used to normalize luciferase activity for each well. Total amounts of transfected DNA were kept constantly at 750 ng per well by the empty vector. At 48 h post-transfection, cells were washed with PBS and lysed with 1 \times Reporter Lysis Buffer (Promega). The extract proteins were assayed for firefly and renilla activity. Both of the assays were performed using Duel Luciferase firefly Assay

Synergy with MITF

+

-

+

-

+

System (Promega) according to the manufacturer's protocol and determined using SIRIUS luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany). All report assays were repeated at least triplicately each time. Data were analyzed using Prism 5 software (GraphPad, Software Inc., San Diego, CA, USA).

Results

IRF4 synergizes with MITF to activate the TYR promoter specifically

We first tested the ability of MITF alone or in combination with IRF4 to transactivate the TYR promoter in pigmentation cells and non-pigmentation cells. As shown in **Figure 1**, in both kinds of cells, transfection with MITF increased the TYR promoter activity as compared with that of the empty vector control. IRF4 alone did not affect TYR promoter significantly. However, IRF4 was able to augment the ability of MITF to transactivate the TYR promoter.

As also shown in **Figure 1**, MITF was also able to activate 4M-box and DCT promoter alone, but did not show synergic effect on these two promoters with IRF4. Hence, the cooperative effects were specific for TYR promoter.

Analysis of the IRF4 DNA binding sites in the TYR promoter

There were four potential IRF4 binding sites (BS1-4) in the Tyrosinase minimal promoter (**Figure 2A**). To further investigate the importance of DNA binding in the synergic effect of IRF4, we generated eight reporter plasmids with mutant TYR promoters (**Figure 2B**).

Mutation one, two, three of these IRF4 DNA binding sites (TYR1/TYR2/TYR3/TYR4/TYR5)

Synergic activation of TYR promoter by MITF and IRF4

did not disrupt the cooperative effects of MITF and IRF4. However, IRF4 failed to argue the trans-activity of MITF on the promoter with all four IRF4-binding sites mutated (TYR7). We further make a truncated reporter including E-box and BS4 only (TYR6). As shown in **Figure 2C**, MITF was still able to transactivate TYR6, indicated E-box alone was sufficient to initiate the transactivation of TYR by MITF. Importantly, IRF4 retained its synergic effect on TYR6, indicating BS4 alone was sufficient for the synergic effect. Nevertheless, The synergic effect of IRF4 was lost on TYR7 with only functional E-box, confirming IRF4-binding sites (BS1-BS4) were all required for the synergy.

Functional synergic domain in IRF4 and MITF

To map the functional domains in IRF4 that are critical for the synergic effect, we generated a series of C-terminal truncated IRF4 expression plasmids (**Figure 3A**). As shown in **Figure 3B**, full-length IRF4 (aa1-450), IRF4 (aa1-420) and IRF4 (aa1-207) showed similar synergic effect on TYR promoter. However, IRF4 (aa1-300) and IRF4 (aa1-134) lost the synergic effect with MITF.

Further, we also localized the domain of MITF that is required for its transcriptional synergy with IRF4 by a series of truncated MITF mutant constructs, which were designed based on the known functional domains of MITF (**Figure 4A**). Synergy effect with IRF4 on TYR promoter was only showed in the truncated MITF aa1-293 and aa185-419, both of which containing the bHLH/LZ domain and trans-activation domain (N-terminal or C-terminal individually). Furthermore, The mutant MITF aa1-185, aa185-293 and aa293-419 nearly completely abolished synergy (**Figure 4B**).

Discussion

MITF encodes a member of MYC superfamily transcription factor containing the bHLH-Zip domain. The basic domain used for DNA binding, whereas the HLH and Zip domains are used for homo- and/or heterodimer [14, 15]. Tyrosinase is one of the key enzymes in melanin biosynthesis. It is encoded by the *TYR* gene which is specifically expressed in differentiated melanocytes [16]. MITF alone can binds to the specific E-box motif (CANNTG) within the promoter of TYR and initiates its transcription [16, 17]. Three conserved E-box motifs have been

located in the TYR promoter, named as initiator E-box (position -12 to -7), the M-box (position -104 to -99) and the TDE (tyrosinase distal element) (position -1972 to -1967) respectively. The M-box (an E-box with a flanking T at the 5' end and CT at the 3' end of the CATGTG sequence) has been shown to be essential for the activation of the tyrosinase promoter by MITF. The initiator E-box, and TDE, also act to further increase the level of tyrosinase expression [16-18]. Kluppel *et al.* found that a 270 bp upstream region is sufficient for specific expression in melanocytes and pigmented epithelium of the retina [19]. Our "minimal TYR promoter" (-300 to +80) contains M-box and initiator E-box motifs.

Quantitative ChIP experiments showed that IRF4 may bind at the sites of a proximal (pTYR; around the transcription start site) and a more distant region (dTYR; >1,800 bp upstream of transcription start site) which in both cases is consistent with the presence of E-box motifs in these positions of the TYR promoter [4].

As shown in **Figure 1**, Unlike the TYR promoter, Wild type MITF is able to transactivate the DCT promoter and the artificial promoter containing 4 copies of the M-box (4M-box), but no cooperative effects could be observed with IRF4. IRF4 contains an N-terminal DNA-binding domain that recognizes GAAA/TTTC core motifs [20]. Four potential IRF4 binding sites (BS1-4) in the our Tyrosinase minimal promoter were identified by sequencing (**Figure 2A**). Since there is no IRF4 DNA binding site on DCT or 4M-box promoter by sequencing. Mutating analysis also showed that synergistic effects of MITF and IRF4 on the TYR promoter are mediated through all these IRF4 binding sites. All these results indicated that the DNA binding of IRF4 is required for synergy.

Map the IRF4 and MITF functional synergic domains

The IRF4 protein can be basically divided into two parts: DNA binding domain (DBD), aa1-134 and Functional regulatory domain, aa135-450 (**Figure 3A**). The DBD contains five conserved tryptophan residues [21]. The Functional regulatory domain contains two transactivation domains (TAD): TAD1, aa134-207 and TAD2, aa300-420 and an auto-masking domain (AMD), aa207-300 [20].

Synergic activation of TYR promoter by MITF and IRF4




Figure 4. Identification of MITF sequences involved in transactivation with/without IRF4. A. A schematic representation of the full length MITF and various truncated MITF proteins. Basic-HLH-LZip, region of the basic HLH leucine zipper domains. TA, Transactivation domain. B. HEK293T cells were transiently transfected with the TYR luciferase reporter and full length or truncated MITF mutant expression plasmids with/without IRF4. Luciferase activity is reported as a fold increase relative to reporter alone. Each value represents the mean \pm SD of three replicates from a single assay. The results shown were representative of at least three independent experiments (***) compared to the value from the wt MITF with/without IRF4 and different MITF mutants with/without IRF4, unpaired Student's t-test).

Our results indicated that TAD1 (aa134-207) and TAD2 (aa300-420) of IRF4 participate in the synergic trans-activation with MITF, However the AMD (aa207-300) may serve as a masking region. Our results are consistent with previous reports regarding the cooperation between c-Src and IRF4 [22]. In the study of the interaction of c-Src and IRF4, the region spanning aa255-412, rich in α -helix structure,

was identified to an important domain which could inhibits the cooperational activity.

The bHLH-LZ domain contains a basic domain which is used for DNA binding and HLH and Zip domains that are used for homo- and/or heterodimer formation. Moreover, As important functional domains for the transactivation, two Tyrosinase related different activation domains

Synergic activation of TYR promoter by MITF and IRF4

have been identified in the MITF protein (TA in **Figure 4**) so far [23-25]. As shown in the **Figure 4B**, MITF (aa1-185) and MITF (aa293-419), which are lack of bHLH/LZ domain (DNA binding domain), completely lost the transcriptional activation on TYR promoter and so does the synergic effect with IRF4. MITF (aa185-293), which is lack of transcriptional activation (TA) domains, lost the transcriptional activation on TYR promoter and synergic effect with IRF4 similarly. Notable, Full length MITF, MITF (aa1-293) and MITF (aa185-419) show obvious transactivation of the TYR promoter, synergy with IRF4 also can be observed, all of which contain the bHLH/LZ domain (DNA binding domain) and trans-activation domains in N-terminal and/or C-terminal. Our results indicated that the bHLH/LZ domain and transactivation domain of MITF are both required for the transactivation and synergic effect with IRF4 on TYR promoter.

IRF4 usually as a positive regulator of gene transcription for many cofactors. Some of the Mechanism of IRF4 synergy with other protein has been characterized in the previous studies. IRF4 and PU.1 can form a stable ternary complex to regulate the target gene dependent on DNA [26]. IRF4 can also functionally cooperate with the transcription factor NFATC2 to synergistically regulate the IL4 promoter in T cells without binding DNA [27].

Since IRF4 poorly binds to DNA by itself as a weak transcriptional activator which previously research described [26] and cannot activate the TYR promoter independently. These domains could either form as interaction surface for a co-activator or as a component for the transcription apparatus.

The mechanism of the MITF and IRF4 relative domains in mediating synergy is proposed. MITF may lead a conformational change of IRF4, which lead to strengthen the ability of binding DNA and get expose TAD sequences necessary for trans-activation of TYR. Moreover, the conformational changes in both proteins are also could be involved in this synergy mechanism. Therefore, the formational changed IRF4 may act as a enhancer and induce an MITF conformation which facilitates DNA binding and lead to the increasing production of TYR promoter.

Here we showed that IRF4 potently synergizes with MITF to activate TYR promoter, which is dependent on DNA binding of IRF4. The synergic domains in both IRF4 and MITF were also identified by mutational analysis. This will help to better understand the role of IRF4 in the pigment system and the pathogenic mechanism in WS.

Acknowledgements

This study was supported by National Basic Research and Development Program of China (973 Program) (No. 2014CB541702, to Yong Feng), the National Natural Science Foundation of China (Nos. 81170923, 81470705 to Yong Feng, 81500803 to Hongsheng Chen), The public welfare industry research special fund projects of ministry of health of China (No. 201302001, to Yong Feng). Jian Song is a joint PhD student supported by the scholarship under the State Scholarship Fund (2013-2015). We would like to thank Prof Hideki Murakami and Vachtenheim for generously supplying the materials. We would also like to thank all of the technical staff from the State Key Laboratory of Medical Genetics, Province Key Laboratory of Otolaryngology Critical Disease in Central South University and Center of Medical Genetics in Gent Hospital for their support.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Yong Feng, Department of Otolaryngology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan, People's Republic of China. Tel: +860731-89753745; E-mail: fengyong_hn@hotmail.com

References

- [1] Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Magnusson KP, Manolescu A, Karason A, Palsson A, Thorleifsson G, Jakobsdottir M, Steinberg S, Palsson S, Jonasson F, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Aben KK, Kiemenev LA, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U and Stefansson K. Genetic determinants of hair, eye and skin pigmentation in Europeans. *Nat Genet* 2007; 39: 1443-1452.

Synergic activation of TYR promoter by MITF and IRF4

- [2] Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Jakobsdottir M, Steinberg S, Gudjonsson SA, Palsson A, Thorleifsson G, Palsson S, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Aben KK, Vermeulen SH, Goldstein AM, Tucker MA, Kiemeny LA, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U and Stefansson K. Two newly identified genetic determinants of pigmentation in Europeans. *Nat Genet* 2008; 40: 835-837.
- [3] Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, Hankinson SE, Hu FB, Duffy DL, Zhao ZZ, Martin NG, Montgomery GW, Hayward NK, Thomas G, Hoover RN, Chanock S and Hunter DJ. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. *PLoS Genet* 2008; 4: e1000074.
- [4] Praetorius C, Grill C, Stacey SN, Metcalf AM, Gorkin DU, Robinson KC, Van Otterloo E, Kim RS, Bergsteinsdottir K, Ogmundsdottir MH, Magnúsdottir E, Mishra PJ, Davis SR, Guo T, Zaidi MR, Helgason AS, Sigurdsson MI, Meltzer PS, Merlino G, Petit V, Larue L, Loftus SK, Adams DR, Sobhiahfar U, Emre NC, Pavan WJ, Cornell R, Smith AG, McCallion AS, Fisher DE, Stefansson K, Sturm RA and Steingrimsson E. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. *Cell* 2013; 155: 1022-1033.
- [5] Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Hoiom V, Zhao ZZ, Sturm RA, Soranzo N, Hammond C, Kvaskoff M, Whiteman DC, Mangino M, Hansson J, Newton-Bishop JA, Bataille V, Hayward NK, Martin NG, Bishop DT, Spector TD and Montgomery GW. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. *Am J Hum Genet* 2010; 87: 6-16.
- [6] Grossman A, Mittrucker HW, Nicholl J, Suzuki A, Chung S, Antonio L, Suggs S, Sutherland GR, Siderovski DP and Mak TW. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. *Genomics* 1996; 37: 229-233.
- [7] Sundram U, Harvell JD, Rouse RV and Natkunam Y. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. *Mod Pathol* 2003; 16: 802-810.
- [8] Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R and Steingrimsson E. Novel MITF targets identified using a two-step DNA microarray strategy. *Pigment Cell Melanoma Res* 2008; 21: 665-676.
- [9] Tassabehji M, Newton VE and Read AP. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. *Nat Genet* 1994; 8: 251-255.
- [10] Amai S, Fuse N, Yasumoto K, Sato S, Yajima I, Yamamoto H, Udono T, Durlu YK, Tamai M, Takahashi K and Shibahara S. Identification of a novel isoform of microphthalmia-associated transcription factor that is enriched in retinal pigment epithelium. *Biochem Biophys Res Commun* 1998; 247: 710-715.
- [11] Song J, Feng Y, Acke FR, Coucke P, Vleminckx K and Dhooge IJ. Hearing loss in Waardenburg syndrome: a systematic review. *Clin Genet* 2015; [Epub ahead of print].
- [12] Zhang H, Luo H, Chen H, Mei L, He C, Jiang L, Li JD and Feng Y. Functional analysis of MITF gene mutations associated with Waardenburg syndrome type 2. *FEBS Lett* 2012; 586: 4126-4131.
- [13] Vachtenheim J, Novotna H and Ghanem G. Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. *J Invest Dermatol* 2001; 117: 1505-1511.
- [14] Hughes MJ, Lingrel JB, Krakowsky JM and Anderson KP. A helix-loop-helix transcription factor-like gene is located at the mi locus. *J Biol Chem* 1993; 268: 20687-20690.
- [15] Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA and Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. *Cell* 1993; 74: 395-404.
- [16] Yasumoto K, Yokoyama K, Shibata K, Tomita Y and Shibahara S. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. *Mol Cell Biol* 1995; 15: 1833.
- [17] Bentley NJ, Eisen T and Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. *Mol Cell Biol* 1994; 14: 7996-8006.
- [18] Aksan I and Goding CR. Targeting the microphthalmia basic helix-loop-helix-leucine zipper transcription factor to a subset of E-box elements in vitro and in vivo. *Mol Cell Biol* 1998; 18: 6930-6938.
- [19] Kluppel M, Beermann F, Ruppert S, Schmid E, Hummler E and Schutz G. The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. *Proc Natl Acad Sci U S A* 1991; 88: 3777-3781.

Synergic activation of TYR promoter by MITF and IRF4

- [20] Brass AL, Kehrl E, Eisenbeis CF, Storb U and Singh H. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. *Genes Dev* 1996; 10: 2335-2347.
- [21] Matsuyama T, Grossman A, Mittrucker HW, Siderovski DP, Kiefer F, Kawakami T, Richardson CD, Taniguchi T, Yoshinaga SK and Mak TW. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). *Nucleic Acids Res* 1995; 23: 2127-2136.
- [22] Wang L and Ning S. Interferon regulatory factor 4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells. *J Virol* 2013; 87: 9672-9679.
- [23] Mansky KC, Marfatia K, Purdom GH, Luchin A, Hume DA and Ostrowski MC. The microphthalmia transcription factor (MITF) contains two N-terminal domains required for transactivation of osteoclast target promoters and rescue of mi mutant osteoclasts. *J Leukoc Biol* 2002; 71: 295-303.
- [24] Sato S, Roberts K, Gambino G, Cook A, Kouzarides T and Goding CR. CBP/p300 as a co-factor for the Microphthalmia transcription factor. *Oncogene* 1997; 14: 3083-3092.
- [25] Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Uono T, Saito H, Takahashi K and Shibahara S. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. *J Biol Chem* 2000; 275: 14013-14016.
- [26] Brass AL, Zhu AQ and Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. *EMBO J* 1999; 18: 977-991.
- [27] Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H and Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. *J Exp Med* 2002; 195: 1003-1012.